Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer

The goal of this clinical trial is to evaluate the efficacy of proactive immune tolerance induction of chemotherapy (paclitaxel and carboplatin) for patients with gynecologic cancer. The main questions it aims to answer are: - Does immune tolerance induction during the first three cycles of chemotherapy reduce the incidence of hypersensitivity reactions in the remaining cycles? Participants will: - Undergo immune tolerance induction or standard treatment during the first three cycles of chemotherapy, after which all participants will continue the remaining cycles with standard treatment.